

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/21 - Basic Clinical Chemistry - Serum

Deadline: 09.04.2021

| | | |
|--|--|--|
| RoM = robust average | AV = assigned value | Dmax = acceptable percent difference |
| SD = standard deviation | CRV = certified reference value | LL = lower limit |
| CV = coefficient of variation | RV = reference value | UL = upper limit |
| Ntot = total number of the participants | CVE = consensus value from experts | Neva = number of evaluated participants |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants | Nsuc = number of successful participants |
| | CVPG = consensus value from participants groups | Srel = success (relative) |
| | U _{AV} = expanded uncertainty of the assigned value (k = 2) | |

| Test | [unit] | Comparability | | | | | | | | | | | Traceability | | | | | | | | | | |
|---------------------------------|----------|---------------|------|--------|------------------|------------------|-----|-----------------|------------------|-----|-----|------------------|------------------|------------------|-------|-----------------|------------------|------|----|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{Tot} | N _{Out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (1) Sodium | [mmol/L] | | | | 352 | | | | | | | 0 | | | | | | | | | 352 | 342 | 97% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 128 | 2,0 | 1,5 | 352 | | | | | | | 0 | CRV | 128,3 | 1,9 | 5% | 121 | 135 | | 352 | 345 | 98% | |
| (2) Indirect ISE | | 128 | 1,9 | 1,5 | 310 | 0 | | | | | | | | | | | | | | | 310 | | |
| (3) Direct ISE | | 129 | 2,3 | 1,8 | 42 | 0 | | | | | | | | | | | | | | | 42 | | |
| Sample B | | 141 | 2,1 | 1,5 | 352 | | | | | | | 0 | CRV | 140,4 | 2,1 | 5% | 133 | 148 | | 352 | 344 | 98% | |
| (2) Indirect ISE | | 140 | 2,1 | 1,5 | 310 | 2 | | | | | | | | | | | | | | | 310 | | |
| (3) Direct ISE | | 142 | 3,0 | 2,1 | 42 | 0 | | | | | | | | | | | | | | | 42 | | |
| (2) Potassium | [mmol/L] | | | | 352 | | | | | | | 0 | | | | | | | | | 352 | 341 | 97% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 3,39 | 0,06 | 2,0 | 352 | | | | | | | 0 | CRV | 3,353 | 0,050 | 7% | 3,11 | 3,59 | | 352 | 342 | 97% | |
| (2) Indirect ISE | | 3,39 | 0,06 | 2,0 | 311 | 0 | | | | | | | | | | | | | | | 311 | | |
| (3) Direct ISE | | 3,40 | 0,08 | 2,5 | 41 | 0 | | | | | | | | | | | | | | | 41 | | |
| Sample B | | 6,84 | 0,13 | 1,9 | 352 | | | | | | | 0 | CRV | 6,78 | 0,100 | 7% | 6,3 | 7,26 | | 352 | 346 | 98% | |
| (2) Indirect ISE | | 6,84 | 0,13 | 1,8 | 311 | 0 | | | | | | | | | | | | | | | 311 | | |
| (3) Direct ISE | | 6,88 | 0,21 | 3,1 | 41 | 0 | | | | | | | | | | | | | | | 41 | | |
| (3) Chloride | [mmol/L] | | | | 352 | | | | | | | 352 | 339 | 96% | | | | | | | | | 0 |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 112 | 2,9 | 2,6 | 352 | CVP | 112 | 0,37 | 7% | 104 | 120 | 352 | 341 | 97% | | | | | | | | | 0 |
| (3) Indirect ISE | | 112 | 2,9 | 2,6 | 313 | 0 | | | | | | 313 | | | | | | | | | | | |
| (4) Direct ISE | | 111 | 3,0 | 2,7 | 39 | 0 | | | | | | 39 | | | | | | | | | | | |
| Sample B | | 131 | 3,1 | 2,4 | 352 | CVP | 131 | 0,41 | 7% | 121 | 141 | 352 | 342 | 97% | | | | | | | | | 0 |
| (3) Indirect ISE | | 131 | 3,1 | 2,4 | 313 | 0 | | | | | | 313 | | | | | | | | | | | |
| (4) Direct ISE | | 130 | 2,9 | 2,2 | 39 | 0 | | | | | | 39 | | | | | | | | | | | |
| (4) Calcium | [mmol/L] | | | | 322 | | | | | | | 0 | | | | | | | | | 322 | 314 | 98% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 2,90 | 0,07 | 2,6 | 322 | | | | | | | 0 | CRV | 2,926 | 0,047 | 8% | 2,69 | 3,17 | | 322 | 316 | 98% | |
| (2) Phot. with o-cresolftalexon | | 2,93 | 0,05 | 1,9 | 31 | 0 | | | | | | | | | | | | | | | 31 | | |
| (3) Photom. with arsenazo III | | 2,88 | 0,08 | 3,0 | 190 | 1 | | | | | | | | | | | | | | | 190 | | |
| (4) Photomet. with NM-BAPTA | | 2,92 | 0,06 | 2,0 | 96 | 0 | | | | | | | | | | | | | | | 96 | | |
| Other | | | | | 5 | 0 | | | | | | | | | | | | | | | | | 5 |
| Sample B | | 3,02 | 0,08 | 2,9 | 322 | | | | | | | 0 | CRV | 3,013 | 0,045 | 8% | 2,77 | 3,26 | | 322 | 317 | 98% | |
| (2) Phot. with o-cresolftalexon | | 3,07 | 0,06 | 2,0 | 31 | 0 | | | | | | | | | | | | | | | 31 | | |
| (3) Photom. with arsenazo III | | 3,01 | 0,09 | 3,1 | 190 | 0 | | | | | | | | | | | | | | | 190 | | |
| (4) Photomet. with NM-BAPTA | | 3,04 | 0,07 | 2,5 | 96 | 0 | | | | | | | | | | | | | | | 96 | | |
| Other | | | | | 5 | 0 | | | | | | | | | | | | | | | | | 5 |

4x 6, 1x 99

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/21 - Basic Clinical Chemistry - Serum

Deadline: 09.04.2021

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|----------------------------------|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|-------|------|------------------|------------------|------------------|-------|-----------------|------------------|-------|-------|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (5) Inorganic phosphate | [mmol/L] | | | | 309 | | | | | | | 309 | 296 | 96% | | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,03 | 0,03 | 3,1 | 309 | CVP | 1,03 | ,0045 | 10% | 0,927 | 1,14 | 309 | 298 | 96% | | | | | | | 0 | | |
| (1) UV-molybdate method | | 1,03 | 0,03 | 3,2 | 300 | 0 | | | | | | 300 | | | | | | | | | | | |
| (3) Molybdate-vanadate method | | 1,04 | 0,02 | 2,1 | 5 | 0 | | | | | | 5 | | | | | | | | | | | |
| Other | | | | | 4 | 0 | | | | | | 4 | | | | | | | | | | | |
| | | | | | | 4x2 | | | | | | | | | | | | | | | | | |
| Sample B | | 1,72 | 0,04 | 2,7 | 309 | CVP | 1,72 | ,0065 | 10% | 1,54 | 1,9 | 309 | 304 | 98% | | | | | | | 0 | | |
| (1) UV-molybdate method | | 1,72 | 0,04 | 2,8 | 300 | 0 | | | | | | 300 | | | | | | | | | | | |
| (3) Molybdate-vanadate method | | 1,73 | 0,00 | 0,43 | 5 | 0 | | | | | | 5 | | | | | | | | | | | |
| Other | | | | | 4 | 0 | | | | | | 4 | | | | | | | | | | | |
| | | | | | | 4x2 | | | | | | | | | | | | | | | | | |
| (6) Iron | [µmol/L] | | | | 299 | | | | | | | 299 | 293 | 98% | | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 40,8 | 1,4 | 3,4 | 299 | CVP | 40,8 | 0,20 | 15% | 34,6 | 47 | 299 | 294 | 98% | | | | | | | 0 | | |
| (2) Method with ferrozine/ferene | | 40,8 | 1,4 | 3,5 | 249 | 0 | | | | | | 249 | | | | | | | | | | | |
| (4) Method with TPTZ | | 40,7 | 1,2 | 3,1 | 49 | 0 | | | | | | 49 | | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | 1 | | | | | | | | | | | |
| | | | | | | 1x99 | | | | | | | | | | | | | | | | | |
| Sample B | | 34,1 | 0,91 | 2,7 | 299 | CVP | 34,1 | 0,13 | 15% | 28,9 | 39,3 | 299 | 295 | 99% | | | | | | | 0 | | |
| (2) Method with ferrozine/ferene | | 34,2 | 0,95 | 2,8 | 249 | 0 | | | | | | 249 | | | | | | | | | | | |
| (4) Method with TPTZ | | 33,9 | 0,73 | 2,2 | 49 | 0 | | | | | | 49 | | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | 1 | | | | | | | | | | | |
| | | | | | | 1x99 | | | | | | | | | | | | | | | | | |
| (7) Magnesium | [mmol/L] | | | | 302 | | | | | | | 0 | | | | | | | | | 302 | 289 | 96% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 0,814 | 0,03 | 3,9 | 302 | | | | | | | 0 | | CRV | 0,783 | 0,012 | 15% | 0,665 | 0,901 | 302 | 296 | 98% | |
| (2) Photometry | | 0,821 | 0,02 | 3,5 | 234 | 0 | | | | | | | | | | | | | | | 234 | | |
| (4) UV enzyme method | | 0,791 | 0,03 | 4,0 | 67 | 0 | | | | | | | | | | | | | | | 67 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | 1x99 | | | | | | | | | |
| Sample B | | 2,14 | 0,08 | 4,1 | 302 | | | | | | | 0 | | CRV | 2,121 | 0,032 | 15% | 1,8 | 2,44 | 302 | 293 | 97% | |
| (2) Photometry | | 2,14 | 0,09 | 4,4 | 234 | 0 | | | | | | | | | | | | | | | 234 | | |
| (4) UV enzyme method | | 2,16 | 0,06 | 2,9 | 67 | 0 | | | | | | | | | | | | | | | 67 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | 1x99 | | | | | | | | | |
| (8) Lithium | [mmol/L] | | | | 39 | | | | | | | 0 | | | | | | | | | 39 | 33 | 85% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,47 | 0,07 | 5,0 | 39 | | | | | | | 0 | | CRV | 1,489 | 0,022 | 12% | 1,31 | 1,67 | 39 | 36 | 92% | |
| (1) Flame emission phot. | | 1,43 | 0,08 | 6,2 | 5 | 0 | | | | | | | | | | | | | | | 5 | | |
| (3) ISE | | 1,48 | 0,06 | 4,4 | 16 | 0 | | | | | | | | | | | | | | | 16 | | |
| (4) Photometry | | 1,48 | 0,08 | 5,5 | 16 | 0 | | | | | | | | | | | | | | | 16 | | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | 2 | | |
| | | | | | | | | | | | | | | 2x2 | | | | | | | | | |
| Sample B | | 0,832 | 0,04 | 5,0 | 39 | | | | | | | 0 | | CRV | 0,829 | 0,012 | 12% | 0,729 | 0,929 | 39 | 35 | 90% | |
| (1) Flame emission phot. | | 0,790 | 0,05 | 7,5 | 5 | 0 | | | | | | | | | | | | | | | 5 | | |
| (3) ISE | | 0,869 | 0,05 | 5,8 | 16 | 0 | | | | | | | | | | | | | | | 16 | | |
| (4) Photometry | | 0,816 | 0,03 | 4,2 | 16 | 0 | | | | | | | | | | | | | | | 16 | | |

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/21 - Basic Clinical Chemistry - Serum

Deadline: 09.04.2021

| Test | [unit] | Comparability | | | | | | | | | | Traceability | | | | | | | | | | | |
|-------------------------------|-----------|---------------|------|--------|------------------|------------------|------|-----------------|------------------|------|------|------------------|------------------|------------------|-------|-----------------|------------------|-------|----|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (8) Lithium | [mmol/L] | | | | 39 | | | | | | | 0 | | | | | | | | | 39 | 33 | 85% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample B | | 0,832 | 0,04 | 5,0 | 39 | | | | | | | 0 | CRV | 0,829 | 0,012 | 12% | 0,729 | 0,929 | | 39 | 35 | 90% | |
| Other | | | | | 2 | 0 | | | | | | | | 2x2 | | | | | | | 2 | | |
| (9) Total protein | [g/L] | | | | 334 | | | | | | | 0 | | | | | | | | | 334 | 320 | 96% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 70,8 | 1,8 | 2,6 | 334 | | | | | | | 0 | CRV | 72,1 | 1,7 | 9% | 65,6 | 78,6 | | 334 | 326 | 98% | |
| (1) Biuret | | 70,8 | 1,8 | 2,6 | 334 | 0 | | | | | | | | | | | | | | | 334 | | |
| Sample B | | 84,4 | 2,7 | 3,2 | 334 | | | | | | | 0 | CRV | 84,3 | 2,0 | 9% | 76,7 | 91,9 | | 334 | 322 | 96% | |
| (1) Biuret | | 84,4 | 2,7 | 3,2 | 334 | 0 | | | | | | | | | | | | | | | 334 | | |
| (10) Albumin | [g/L] | | | | 327 | | | | | | | 327 | 322 | 98% | | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 44,7 | 1,6 | 3,5 | 327 | CVP | 44,7 | 0,21 | 10% | 40,2 | 49,2 | 327 | 322 | 98% | | | | | | | 0 | | |
| (1) BCG | | 44,8 | 1,5 | 3,4 | 304 | 0 | | | | | | 304 | | | | | | | | | | | |
| (2) BCP | | 43,1 | 1,3 | 2,9 | 23 | 0 | | | | | | 23 | | | | | | | | | | | |
| Sample B | | 52,4 | 1,8 | 3,5 | 327 | CVP | 52,4 | 0,25 | 10% | 47,1 | 57,7 | 327 | 323 | 99% | | | | | | | 0 | | |
| (1) BCG | | 52,6 | 1,8 | 3,4 | 304 | 0 | | | | | | 304 | | | | | | | | | | | |
| (2) BCP | | 50,8 | 1,5 | 3,0 | 23 | 0 | | | | | | 23 | | | | | | | | | | | |
| (11) Osmolality | [mmol/kg] | | | | 126 | | | | | | | 126 | 124 | 98% | | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 300 | 5,8 | 1,9 | 126 | CVP | 300 | 1,3 | 5% | 285 | 315 | 126 | 125 | 99% | | | | | | | 0 | | |
| (1) Osmometer | | 300 | 5,8 | 1,9 | 124 | 0 | | | | | | 124 | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | 2 | | | | | | | | | | | |
| Sample B | | 329 | 7,1 | 2,2 | 126 | CVP | 329 | 1,6 | 5% | 312 | 346 | 126 | 124 | 98% | | | | | | | 0 | | |
| (1) Osmometer | | 330 | 7,0 | 2,1 | 124 | 0 | | | | | | 124 | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | 2 | | | | | | | | | | | |
| (12) Lactate | [mmol/L] | | | | 152 | | | | | | | 152 | 149 | 98% | | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 2,01 | 0,09 | 4,8 | 152 | CVP | 2,01 | 0,019 | 15% | 1,7 | 2,32 | 152 | 149 | 98% | | | | | | | 0 | | |
| (1) UV enzyme method | | 2,00 | 0,08 | 4,4 | 62 | 0 | | | | | | 62 | | | | | | | | | | | |
| (2) Enzyme electrodes | | 2,15 | 0,13 | 6,1 | 10 | 0 | | | | | | 10 | | | | | | | | | | | |
| (3) Photometric enzyme method | | 2,00 | 0,08 | 4,4 | 79 | 0 | | | | | | 79 | | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | 1 | | | | | | | | | | | |
| Sample B | | 2,49 | 0,13 | 5,3 | 152 | CVP | 2,49 | 0,026 | 15% | 2,11 | 2,87 | 152 | 150 | 99% | | | | | | | 0 | | |
| (1) UV enzyme method | | 2,48 | 0,12 | 4,8 | 62 | 0 | | | | | | 62 | | | | | | | | | | | |
| (2) Enzyme electrodes | | 2,66 | 0,12 | 4,4 | 10 | 0 | | | | | | 10 | | | | | | | | | | | |
| (3) Photometric enzyme method | | 2,47 | 0,13 | 5,2 | 79 | 0 | | | | | | 79 | | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | 1 | | | | | | | | | | | |
| (13) Bilirubin total | [µmol/L] | | | | 356 | | | | | | | 0 | | | | | | | | | 356 | 342 | 96% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 28,8 | 2,8 | 9,7 | 356 | | | | | | | 0 | CRV | 27,7 | 0,70 | 21% | 21,8 | 33,6 | | 356 | 346 | 97% | |

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/21 - Basic Clinical Chemistry - Serum

Deadline: 09.04.2021

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|---|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|------|------|------------------|------------------|------------------|-------|-----------------|------------------|------|------|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (13) Bilirubin total | | | | | 356 | | | | | | | 0 | | | | | | | | | 356 | 342 | 96% |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 28,8 | 2,8 | 9,7 | 356 | | | | | | | 0 | | CRV | 27,7 | 0,70 | 21% | 21,8 | 33,6 | | 356 | 346 | 97% |
| (1) Jendrassik-Gróf | | 28,8 | 2,5 | 8,7 | 56 | 0 | | | | | | | | | | | | | | | 56 | | |
| (2) DCA, DPD | | 28,5 | 2,8 | 9,9 | 261 | 2 | | | | | | | | | | | | | | | 261 | | |
| (4) Oxidation-reduction methods | | 30,7 | 2,0 | 6,6 | 37 | 0 | | | | | | | | | | | | | | | 37 | | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | 2 | | |
| Sample B | | 77,1 | 6,0 | 7,8 | 356 | | | | | | | 0 | | CRV | 74,9 | 1,6 | 21% | 59,1 | 90,7 | | 356 | 345 | 97% |
| (1) Jendrassik-Gróf | | 77,8 | 5,6 | 7,1 | 56 | 0 | | | | | | | | | | | | | | | 56 | | |
| (2) DCA, DPD | | 76,2 | 5,8 | 7,6 | 261 | 0 | | | | | | | | | | | | | | | 261 | | |
| (4) Oxidation-reduction methods | | 82,8 | 4,2 | 5,1 | 37 | 0 | | | | | | | | | | | | | | | 37 | | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | 2 | | |
| | | | | | | | | | | | | | | 2x 99 | | | | | | | | | |
| (15) Cholesterol | | | | | 341 | | | | | | | 8 | 7 | 88% | | | | | | | 333 | 314 | 94% |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 3,87 | 0,13 | 3,3 | 341 | | | | | | | 8 | 7 | 88% | | | | | | | 333 | 328 | 98% |
| (1) Enzyme method CHOD-PAP | | 3,87 | 0,12 | 3,2 | 333 | 0 | | | | | | | | CRV | 3,906 | 0,039 | 9% | 3,55 | 4,26 | | 333 | | |
| (1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension) | | 3,58 | 0,23 | 6,4 | 8 | 0 | CVPG | 3,58 | 0,17 | 7,5% | 3,31 | 3,85 | | | | | | | | | | | |
| Sample B | | 5,12 | 0,19 | 3,8 | 341 | | | | | | | 8 | 8 | 100% | | | | | | | 333 | 315 | 95% |
| (1) Enzyme method CHOD-PAP | | 5,13 | 0,19 | 3,7 | 333 | 0 | | | | | | | | CRV | 5,31 | 0,053 | 9% | 4,83 | 5,79 | | 333 | | |
| (1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension) | | 4,72 | 0,22 | 4,6 | 8 | 0 | CVPG | 4,72 | 0,16 | 7,5% | 4,36 | 5,08 | | | | | | | | | | | |
| | | | | | | | | | | | | | | 2x 99 | | | | | | | | | |
| (16) Glucose | | | | | 361 | | | | | | | 0 | | | | | | | | | 361 | 348 | 96% |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 3,86 | 0,11 | 3,0 | 361 | | | | | | | 0 | | CRV | 3,89 | 0,039 | 8% | 3,57 | 4,21 | | 361 | 354 | 98% |
| (1) GOD photometry | | 3,94 | 0,13 | 3,4 | 77 | 0 | | | | | | | | | | | | | | | 77 | | |
| (2) GOD electrochemical | | 3,93 | 0,11 | 2,8 | 5 | 0 | | | | | | | | | | | | | | | 5 | | |
| (3) Method with hexokinase | | 3,84 | 0,10 | 2,7 | 279 | 0 | | | | | | | | | | | | | | | 279 | | |
| Sample B | | 11,7 | 0,33 | 2,8 | 361 | | | | | | | 0 | | CRV | 11,84 | 0,12 | 8% | 10,8 | 12,8 | | 361 | 351 | 97% |
| (1) GOD photometry | | 11,8 | 0,34 | 2,9 | 77 | 0 | | | | | | | | | | | | | | | 77 | | |
| (2) GOD electrochemical | | 11,9 | 0,16 | 1,4 | 5 | 0 | | | | | | | | | | | | | | | 5 | | |
| (3) Method with hexokinase | | 11,7 | 0,33 | 2,8 | 279 | 1 | | | | | | | | | | | | | | | 279 | | |
| (17) Uric acid | | | | | 351 | | | | | | | 0 | | | | | | | | | 351 | 344 | 98% |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 459 | 13 | 2,9 | 351 | | | | | | | 0 | | CRV | 456,3 | 4,6 | 12% | 401 | 512 | | 351 | 346 | 99% |
| (2) Enzyme-photomet. m. | | 459 | 13 | 2,9 | 351 | 0 | | | | | | | | | | | | | | | 351 | | |
| Sample B | | 361 | 9,8 | 2,7 | 351 | | | | | | | 0 | | CRV | 361,4 | 3,6 | 12% | 318 | 405 | | 351 | 345 | 98% |
| (2) Enzyme-photomet. m. | | 361 | 9,8 | 2,7 | 351 | 0 | | | | | | | | | | | | | | | 351 | | |
| (18) Urea | | | | | 358 | | | | | | | 0 | | | | | | | | | 358 | 349 | 97% |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 31,1 | 1,2 | 4,0 | 358 | | | | | | | 0 | | CRV | 31,96 | 0,32 | 15% | 27,1 | 36,8 | | 358 | 352 | 98% |
| (1) UV enzymatic m.(GMD) | | 31,0 | 1,2 | 4,0 | 352 | 0 | | | | | | | | | | | | | | | 352 | | |
| Other | | | | | 6 | 0 | | | | | | | | | | | | | | | 6 | | |
| Sample B | | 20,0 | 0,72 | 3,6 | 358 | | | | | | | 0 | | CRV | 20,74 | 0,21 | 15% | 17,6 | 23,9 | | 358 | 350 | 98% |
| | | | | | | | | | | | | | | 2x 2, 4x 5 | | | | | | | | | |

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/21 - Basic Clinical Chemistry - Serum

Deadline: 09.04.2021

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|--|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|----|------|------------------|------------------|------------------|--------|-----------------|------------------|------|------|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (18) Urea | [mmol/L] | | | | 358 | | | | | | | 0 | | | | | | | | | 358 | 349 | 97% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample B | | 20,0 | 0,72 | 3,6 | 358 | | | | | | | 0 | CRV | 20,74 | 0,21 | 15% | 17,6 | 23,9 | | 358 | 350 | 98% | |
| (1) UV enzymatic m.(GMD) | | 20,0 | 0,72 | 3,6 | 352 | 0 | | | | | | | | | | | | | | | 352 | | |
| Other | | | | | 6 | 0 | | | | | | | | | | | | | | | | 6 | |
| | | | | | | | | | | | | | 2x 2, 4x 5 | | | | | | | | | | |
| (19) Creatinine | [µmol/L] | | | | 361 | | | | | | | 0 | | | | | | | | | 361 | 350 | 97% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 120 | 4,8 | 4,0 | 361 | | | | | | | 0 | CRV | 119,6 | 1,7 | 13% | 104 | 136 | | 361 | 352 | 98% | |
| (1) Jaffe | | 122 | 4,5 | 3,7 | 174 | 0 | | | | | | | | | | | | | | | | 174 | |
| (3) Enzyme | | 118 | 4,3 | 3,6 | 186 | 0 | | | | | | | | | | | | | | | | 186 | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | | | 1 |
| Sample B | | 350 | 15 | 4,2 | 361 | | | | | | | 0 | CRV | 351,5 | 5,3 | 13% | 305 | 398 | | 361 | 354 | 98% | |
| (1) Jaffe | | 353 | 20 | 5,7 | 174 | 0 | | | | | | | | | | | | | | | | 174 | |
| (3) Enzyme | | 348 | 9,5 | 2,7 | 186 | 0 | | | | | | | | | | | | | | | | 186 | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | | | 1 |
| | | | | | | | | | | | | | 1x 0 | | | | | | | | | | |
| (20) Triacylglycerols | [mmol/L] | | | | 340 | | | | | | | 0 | | | | | | | | | 340 | 324 | 95% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,81 | 0,06 | 3,3 | 340 | | | | | | | 0 | CRV | 1,771 | 0,018 | 15% | 1,5 | 2,04 | | 340 | 336 | 99% | |
| (1) Photometric enzyme (GPO-PAP) | | 1,81 | 0,06 | 3,3 | 325 | 0 | | | | | | | | | | | | | | | | 325 | |
| (2) Enzymatic UV method | | 1,81 | 0,04 | 2,7 | 15 | 0 | | | | | | | | | | | | | | | | | 15 |
| Sample B | | 1,09 | 0,07 | 6,9 | 340 | | | | | | | 0 | CRV | 1,032 | 0,0100 | 15% | 0,877 | 1,19 | | 340 | 324 | 95% | |
| (1) Photometric enzyme (GPO-PAP) | | 1,09 | 0,07 | 7,0 | 325 | 0 | | | | | | | | | | | | | | | | 325 | |
| (2) Enzymatic UV method | | 1,08 | 0,06 | 6,2 | 15 | 0 | | | | | | | | | | | | | | | | | 15 |
| (21) ALP | [µkat/L] | | | | 350 | | | | | | | 0 | | | | | | | | | 350 | 342 | 98% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 3,55 | 0,32 | 9,0 | 350 | | | | | | | 0 | CRV | 3,62 | 0,100 | 28% | 2,6 | 4,64 | | 350 | 343 | 98% | |
| (3) IFCC method | | 3,55 | 0,32 | 9,0 | 348 | 0 | | | | | | | | | | | | | | | | 348 | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | | | 2 |
| Sample B | | 6,21 | 0,59 | 9,6 | 350 | | | | | | | 0 | CRV | 6,34 | 0,18 | 28% | 4,56 | 8,12 | | 350 | 345 | 99% | |
| (3) IFCC method | | 6,21 | 0,59 | 9,5 | 348 | 0 | | | | | | | | | | | | | | | | 348 | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | | | 2 |
| | | | | | | | | | | | | | | 2x 1 | | | | | | | | | |
| (22) alpha-amylase | [µkat/L] | | | | 333 | | | | | | | 7 | 7 100% | | | | | | | | 326 | 314 | 96% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 5,46 | 0,35 | 6,3 | 333 | | | | | | | 7 | 7 100% | | | | | | | | 326 | 314 | 96% |
| (1) IFCC method | | 5,45 | 0,33 | 6,1 | 325 | 0 | | | | | | | | CRV | 5,35 | 0,16 | 15% | 4,54 | 6,16 | | | 325 | |
| (1) IFCC method; (149) Siemens (Dade, BN, Dimension) | | 6,63 | 0,19 | 2,9 | 7 | 0 | CVPG | 6,63 | 0,19 | 9% | 6,03 | 7,23 | 7 | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | | | 1 |
| Sample B | | 7,44 | 0,48 | 6,4 | 333 | | | | | | | 7 | 7 100% | | | | | | | | 326 | 317 | 97% |
| (1) IFCC method | | 7,42 | 0,46 | 6,3 | 325 | 0 | | | | | | | | CRV | 7,32 | 0,21 | 15% | 6,22 | 8,42 | | | 325 | |
| (1) IFCC method; (149) Siemens (Dade, BN, Dimension) | | 9,09 | 0,38 | 4,1 | 7 | 0 | CVPG | 9,09 | 0,37 | 9% | 8,27 | 9,91 | 7 | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/21 - Basic Clinical Chemistry - Serum

Deadline: 09.04.2021

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|--------------------------------------|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|-----|-------|------------------|------------------|------------------|------------|-----------------|------------------|-----|------|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (22) alpha-amylase | | | | | 333 | | | | | | | 7 | 7 | 100% | | | | | | | 326 | 314 | 96% |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample B | | 7,44 | 0,48 | 6,4 | 333 | | | | | | | 7 | 7 | 100% | | | | | | | 326 | 317 | 97% |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x99 | | | | | | | | |
| (23) AST | | | | | 358 | | | | | | | 0 | | | | | | | | | 358 | 353 | 99% |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,79 | 0,07 | 4,3 | 358 | | | | | | | 0 | | | CRV | 1,771 | 0,045 | 15% | 1,5 | 2,04 | 358 | 353 | 99% |
| (1) IFCC method | | 1,79 | 0,07 | 4,3 | 358 | 2 | | | | | | | | | | | | | | | 358 | | |
| Sample B | | 2,69 | 0,12 | 4,6 | 358 | | | | | | | 0 | | | CRV | 2,668 | 0,059 | 15% | 2,26 | 3,07 | 358 | 354 | 99% |
| (1) IFCC method | | 2,69 | 0,12 | 4,6 | 358 | 0 | | | | | | | | | | | | | | | 358 | | |
| (24) ALT | | | | | 357 | | | | | | | 0 | | | | | | | | | 357 | 347 | 97% |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 2,26 | 0,13 | 5,9 | 357 | | | | | | | 0 | | | CRV | 2,213 | 0,051 | 15% | 1,88 | 2,55 | 357 | 347 | 97% |
| (1) IFCC method | | 2,26 | 0,13 | 5,9 | 357 | 0 | | | | | | | | | | | | | | | 357 | | |
| Sample B | | 3,98 | 0,21 | 5,2 | 357 | | | | | | | 0 | | | CRV | 3,982 | 0,088 | 15% | 3,38 | 4,58 | 357 | 351 | 98% |
| (1) IFCC method | | 3,98 | 0,21 | 5,2 | 357 | 0 | | | | | | | | | | | | | | | 357 | | |
| (26) CK | | | | | 319 | | | | | | | 0 | | | | | | | | | 319 | 306 | 96% |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 6,83 | 0,43 | 6,3 | 319 | | | | | | | 0 | | | CRV | 7,12 | 0,18 | 20% | 5,69 | 8,55 | 319 | 311 | 97% |
| (1) IFCC method | | 6,83 | 0,43 | 6,3 | 319 | 0 | | | | | | | | | | | | | | | 319 | | |
| Sample B | | 8,74 | 0,65 | 7,4 | 319 | | | | | | | 0 | | | CRV | 9,1 | 0,30 | 20% | 7,28 | 11 | 319 | 309 | 97% |
| (1) IFCC method | | 8,74 | 0,65 | 7,4 | 319 | 0 | | | | | | | | | | | | | | | 319 | | |
| (27) gamma-GT | | | | | 353 | | | | | | | 0 | | | | | | | | | 353 | 341 | 97% |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,27 | 0,06 | 4,9 | 353 | | | | | | | 0 | | | CRV | 1,32 | 0,038 | 15% | 1,12 | 1,52 | 353 | 342 | 97% |
| (1) IFCC method | | 1,27 | 0,06 | 4,8 | 352 | 0 | | | | | | | | | | | | | | | 352 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | 1 | | |
| Sample B | | 2,08 | 0,10 | 4,8 | 353 | | | | | | | 0 | | | 1x0 CRV | 2,102 | 0,054 | 15% | 1,78 | 2,42 | 353 | 346 | 98% |
| (1) IFCC method | | 2,07 | 0,09 | 4,8 | 352 | 0 | | | | | | | | | | | | | | | 352 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x0 | | | | | | | | |
| (28) LD | | | | | 256 | | | | | | | 0 | | | | | | | | | 256 | 250 | 98% |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 6,10 | 0,18 | 3,0 | 256 | | | | | | | 0 | | | CRV | 6,04 | 0,13 | 18% | 4,95 | 7,13 | 256 | 251 | 98% |
| (3) IFCC method | | 6,10 | 0,18 | 3,0 | 256 | 0 | | | | | | | | | | | | | | | 256 | | |
| Sample B | | 4,97 | 0,20 | 4,0 | 256 | | | | | | | 0 | | | CRV | 4,93 | 0,12 | 18% | 4,04 | 5,82 | 256 | 253 | 99% |
| (3) IFCC method | | 4,97 | 0,20 | 4,0 | 256 | 0 | | | | | | | | | | | | | | | 256 | | |
| (29) Lipase | | | | | 162 | | | | | | | 146 | 142 | 97% | | | | | | | 0 | | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,21 | 0,11 | 9,2 | 162 | | | | | | | 146 | 143 | 98% | | | | | | | 0 | | |
| (0) Not specified; (1) Abbott | | 1,23 | 0,08 | 6,6 | 28 | 0 | CVPG | 1,23 | 0,038 | 24% | 0,934 | 1,53 | | | | | | | | 28 | | | |
| (0) Not specified; (46) Erba Lachema | | 1,06 | 0,01 | 1,4 | 5 | 0 | CVPG | 1,06 | 0,042 | 24% | 0,805 | 1,32 | | | | | | | | 5 | | | |

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/21 - Basic Clinical Chemistry - Serum

Deadline: 09.04.2021

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | | |
|---|----------|---------------|------|--------|------------------|------------------|--------------|--|------------------|-----|-------|------------------|------------------|------------------|-----|-----------------|------------------|----|----|------------------|------------------|------------------|---|--|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | | |
| (29) Lipase | [µkat/L] | | | | 162 | | | | | | | 146 | 142 | 97% | | | | | | | | | 0 | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,21 | 0,11 | 9,2 | 162 | | | | | | | 146 | 143 | 98% | | | | | | | | | 0 | |
| (0) Not specified; (58) Beckman Coulter (AU) | | 1,21 | 0,04 | 3,3 | 28 | 0 | CVPG | 1,21 | 0,018 | 24% | 0,919 | 1,51 | | | 28 | | | | | | | | | |
| (0) Not specified; (60) Roche | | 1,15 | 0,04 | 4,3 | 54 | 0 | CVPG | 1,15 | 0,016 | 24% | 0,874 | 1,43 | | | 54 | | | | | | | | | |
| (0) Not specified; (116) Sentinel Diagnostics | | 1,15 | 0,02 | 1,9 | 7 | 0 | CVPG | 1,15 | 0,022 | 24% | 0,874 | 1,43 | | | 7 | | | | | | | | | |
| (0) Not specified; (162) Siemens (Atellica) | | 1,36 | 0,05 | 3,7 | 14 | 0 | CVPG | 1,36 | 0,033 | 24% | 1,03 | 1,69 | | | 14 | | | | | | | | | |
| (0) Not specified; (179) Siemens | | 1,37 | 0,09 | 7,0 | 10 | 0 | CVPG | 1,37 | 0,074 | 24% | 1,04 | 1,7 | | | 10 | | | | | | | | | |
| Other | | | | | 16 | 0 | | | | | | | | | 0 | | | | | | | | | |
| | | | | | | | | 4x 0/12, 3x 0/49, 3x 0/149, 3x 0/177, 3x 0/178 | | | | | | | | | | | | | | | | |
| Sample B | | 2,02 | 0,19 | 9,2 | 162 | | | | | | | 146 | 143 | 98% | | | | | | | | | 0 | |
| (0) Not specified; (1) Abbott | | 1,94 | 0,12 | 5,9 | 28 | 0 | CVPG | 1,94 | 0,053 | 24% | 1,47 | 2,41 | | | 28 | | | | | | | | | |
| (0) Not specified; (46) Erba Lachema | | 1,66 | 0,10 | 6,3 | 5 | 0 | CVPG | 1,66 | 0,29 | 24% | 1,26 | 2,06 | | | 5 | | | | | | | | | |
| (0) Not specified; (58) Beckman Coulter (AU) | | 2,02 | 0,06 | 3,4 | 28 | 0 | CVPG | 2,02 | 0,032 | 24% | 1,53 | 2,51 | | | 28 | | | | | | | | | |
| (0) Not specified; (60) Roche | | 2,00 | 0,07 | 4,0 | 54 | 0 | CVPG | 2,00 | 0,027 | 24% | 1,52 | 2,48 | | | 54 | | | | | | | | | |
| (0) Not specified; (116) Sentinel Diagnostics | | 2,03 | 0,03 | 1,5 | 7 | 0 | CVPG | 2,03 | 0,029 | 24% | 1,54 | 2,52 | | | 7 | | | | | | | | | |
| (0) Not specified; (162) Siemens (Atellica) | | 2,30 | 0,06 | 2,8 | 14 | 0 | CVPG | 2,30 | 0,043 | 24% | 1,74 | 2,86 | | | 14 | | | | | | | | | |
| (0) Not specified; (179) Siemens | | 2,38 | 0,22 | 9,2 | 10 | 0 | CVPG | 2,38 | 0,17 | 24% | 1,8 | 2,96 | | | 10 | | | | | | | | | |
| Other | | | | | 16 | 0 | | | | | | | | | 0 | | | | | | | | | |
| | | | | | | | | 4x 0/12, 3x 0/49, 3x 0/149, 3x 0/177, 3x 0/178 | | | | | | | | | | | | | | | | |
| (30) Cholinesterase | [µkat/L] | | | | 116 | | | | | | | 106 | 98 | 92% | | | | | | | | | 0 | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 120 | 5,3 | 4,4 | 116 | | | | | | | 106 | 100 | 94% | | | | | | | | | 0 | |
| (1) Standard method | | 119 | 4,4 | 3,7 | 106 | 0 | CVP | 119 | 1,1 | 12% | 104 | 134 | | | 106 | | | | | | | | | |
| (2) Siemens | | 140 | 6,2 | 4,4 | 10 | 0 | CVPG | 140 | 4,8 | 12% | 123 | 157 | | | 0 | | | | | | | | | |
| Sample B | | 150 | 7,5 | 5,0 | 116 | | | | | | | 106 | 98 | 92% | | | | | | | | | 0 | |
| (1) Standard method | | 149 | 5,9 | 4,0 | 106 | 0 | CVP | 149 | 1,4 | 12% | 131 | 167 | | | 106 | | | | | | | | | |
| (2) Siemens | | 175 | 9,0 | 5,2 | 10 | 0 | CVPG | 175 | 7,0 | 12% | 154 | 196 | | | 0 | | | | | | | | | |
| (31) Albumin (elpho) | [-] | | | | 80 | | | | | | | 80 | 77 | 96% | | | | | | | | | 0 | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 0,629 | 0,04 | 6,6 | 80 | | CVP | 0,629 | 0,011 | 15% | 0,534 | 0,724 | | | 80 | 79 | 99% | | | | | | 0 | |
| (0) Not specified | | 0,629 | 0,04 | 6,6 | 80 | 0 | | | | | | | | | 80 | | | | | | | | | |
| Sample B | | 0,619 | 0,04 | 7,6 | 80 | | CVP | 0,619 | 0,013 | 15% | 0,526 | 0,712 | | | 80 | 77 | 96% | | | | | | 0 | |
| (0) Not specified | | 0,619 | 0,04 | 7,6 | 80 | 0 | | | | | | | | | 80 | | | | | | | | | |
| (32) gamma-globuline (elpho) | [-] | | | | 80 | | | | | | | 80 | 79 | 99% | | | | | | | | | 0 | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 0,137 | 0,01 | 12 | 80 | | CVP | 0,137 | 0,0044 | 30% | 0,095 | 0,179 | | | 80 | 80 | 100% | | | | | | 0 | |
| (0) Not specified | | 0,137 | 0,01 | 12 | 80 | 0 | | | | | | | | | 80 | | | | | | | | | |
| Sample B | | 0,135 | 0,01 | 13 | 80 | | CVP | 0,135 | 0,0047 | 30% | 0,094 | 0,176 | | | 80 | 79 | 99% | | | | | | 0 | |
| (0) Not specified | | 0,135 | 0,01 | 13 | 80 | 0 | | | | | | | | | 80 | | | | | | | | | |

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/21 - Basic Clinical Chemistry - Serum

Deadline: 09.04.2021

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|--------------------------------------|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|------|------|------------------|------------------|------------------|----|-----------------|------------------|----|----|------------------|------------------|------------------|---|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (35) alpha-amylase pancreatic | [µkat/L] | | | | 101 | | | | | | | 101 | 98 | 97% | | | | | | | | | 0 |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 4,72 | 0,23 | 4,8 | 101 | CVP | 4,72 | 0,055 | 18% | 3,87 | 5,57 | 101 | 98 | 97% | | | | | | | | | 0 |
| (1) With IFCC calibration | | 4,72 | 0,23 | 4,8 | 101 | 0 | | | | | | 101 | | | | | | | | | | | |
| Sample B | | 6,42 | 0,31 | 4,8 | 101 | CVP | 6,42 | 0,075 | 18% | 5,26 | 7,58 | 101 | 98 | 97% | | | | | | | | | 0 |
| (1) With IFCC calibration | | 6,42 | 0,31 | 4,8 | 101 | 0 | | | | | | 101 | | | | | | | | | | | |
| (36) Calcium ionised | [mmol/L] | | | | 52 | | | | | | | 52 | 52 | 100% | | | | | | | | | 0 |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,91 | 0,05 | 2,8 | 52 | CVP | 1,91 | 0,018 | 10% | 1,71 | 2,11 | 52 | 52 | 100% | | | | | | | | | 0 |
| (2) Direct ISE | | 1,91 | 0,05 | 2,7 | 49 | 0 | | | | | | 49 | | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | 3 | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Sample B | | 1,95 | 0,05 | 2,8 | 52 | CVP | 1,95 | 0,018 | 10% | 1,75 | 2,15 | 52 | 52 | 100% | | | | | | | | | 0 |
| (2) Direct ISE | | 1,95 | 0,05 | 2,7 | 49 | 0 | | | | | | 49 | | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | 3 | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |

st_kn_np

End of report

Printed: 20.04.2021